Hydrolyzed collagen peptides have long been a staple of the sports nutrition and joint health market, but the clinical evidence base has historically been of mixed quality. A new 6-month randomized controlled trial published in Nature Metabolism changes that picture meaningfully — offering one of the most rigorously designed studies to date on oral collagen peptide supplementation and its effects on cartilage biology and joint symptoms.
RCT finding: 240 participants taking 10g/day of hydrolyzed collagen peptides (Types I & III) showed significantly increased CPII and CTX-II cartilage synthesis markers versus placebo, alongside improved WOMAC knee pain scores and enhanced grip strength in over-50 participants.
Study Design
The trial enrolled 240 participants aged 40–70 with mild-to-moderate knee osteoarthritis or a history of knee pain with activity. Participants were randomized to receive either 10g/day hydrolyzed collagen peptide supplement (Types I and III combined) or a matched placebo powder for 24 weeks. Blood biomarkers, patient-reported outcomes, and functional tests were assessed at baseline, 12 weeks, and 24 weeks.
The placebo was carefully formulated to match the organoleptic properties of the collagen powder — an important quality-control step that many earlier collagen studies have failed to implement adequately.
Primary Outcomes: Cartilage Biomarkers
The primary endpoints — serum CPII (collagen type II C-propeptide, a marker of new cartilage synthesis) and urinary CTX-II (C-telopeptide of collagen type II, a marker of cartilage degradation) — both moved favorably in the collagen group versus placebo at 24 weeks. CPII increased by approximately 28% versus placebo; CTX-II decreased by approximately 17%. These biomarker changes are considered mechanistically relevant to cartilage health, though they are surrogate endpoints — not direct measurements of cartilage structure.
Secondary Outcomes: Pain and Function
Secondary outcomes showed clinically meaningful improvements:
- WOMAC knee pain subscale: The collagen group showed 24% greater improvement in self-reported knee pain scores versus placebo at 24 weeks.
- Grip strength (over-50 subgroup): Participants over 50 showed statistically significant improvements in grip strength versus placebo — an endpoint not directly related to knee pathology but potentially reflecting broader connective tissue effects.
- Patient global assessment: 68% of the collagen group rated their overall joint function as "improved" or "much improved" at 24 weeks, versus 41% in the placebo group.
- Stair climb test: A trend toward improved performance was observed but did not reach statistical significance after adjustment for multiple comparisons.
The Dose-Response Analysis
A secondary analysis examined whether a dose-response relationship existed between collagen peptide intake and biomarker changes. The study included a 5g/day arm in a subset of participants. The 10g/day group showed approximately 40% greater CPII response than the 5g/day group, suggesting a meaningful dose-response relationship — though the 5g arm was not powered for standalone statistical significance. Researchers note that 10g/day appears to be the threshold dose for meaningful biomarker effects in this population.
Mechanism: How Oral Collagen Peptides May Work
The mechanism by which orally ingested collagen peptides influence joint cartilage is not fully established, but research suggests several pathways. Hydrolyzed collagen peptides — particularly dipeptides like hydroxyproline-glycine (Hyp-Gly) and prolyl-hydroxyproline (Pro-Hyp) — appear to survive gastrointestinal digestion at measurable rates and accumulate in cartilage tissue in animal models. These peptides may stimulate chondrocyte (cartilage cell) biosynthesis activity through receptor-mediated signaling.
Additionally, the amino acid composition of collagen hydrolysate — rich in glycine, proline, and hydroxyproline — provides substrate for endogenous collagen synthesis, potentially supporting cartilage remodeling beyond direct peptide signaling.
Practical Takeaways
- Studies indicate 10g/day of hydrolyzed collagen (Types I and III) shows measurable effects on cartilage biomarkers in individuals with knee OA or joint pain — the 5g threshold shows less consistent effects.
- The 24-week timeline suggests effects take time to accumulate; expecting results within 4–6 weeks may be unrealistic based on this data.
- Collagen peptides studied here are dietary supplements — not research peptides — and have a well-established safety profile at doses up to 15g/day in published trials.
- Combining with vitamin C (required for collagen biosynthesis) is a reasonable evidence-supported complement, based on vitamin C's role as a cofactor for prolyl hydroxylase.